General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
– The collaboration will leverage General Proximity’s OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets.
– Induced proximity medicines, powered by the OmniTAC™ platform, enable precise modulation of disease-driving and traditionally undruggable proteins.
– General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines.
Excerpt from the Press Release:
SAN FRANCISCO, Nov. 12, 2025 /PRNewswire/ — General Proximity, a biotechnology company discovering and developing the next generation of induced proximity medicines, today announced a strategic multi-target collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute in Boston to apply General Proximity’s proprietary OmniTAC™ discovery platform to oncology programs of interest to Daiichi Sankyo.
Induced proximity medicines enable the precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets. The approach uses small molecules to bring two proteins into close physical proximity and subsequently induce a desired therapeutic effect. The OmniTAC™ platform allows unbiased screening for effector proteins capable of modulating disease-relevant targets, offering a powerful and differentiated approach to drug discovery.
“Daiichi Sankyo is a leader in oncology research and development, and we are excited to work with such a strong collaborator,” said Armand Cognetta, Founder & Chief Executive Officer of General Proximity. “This agreement represents an important validation of our novel induced proximity approach and highlights the potential of our OmniTAC™ discovery platform to deliver innovative solutions for patients.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?